Peptide-based RDC (Radionuclide Drug Conjugate) has multiple applications in both diagnostic imaging and targeted therapy through cancer treatment.

With wealthy experience and good-conditioned equipment, Rdcthera has a professional RDC development platform and can provide radionuclide-peptide conjugation service, as well as other RDC development services.

Overview of Radionuclide Peptide Conjugation Services

Peptides are widely used as targeting molecules in RDC. Compared to antibodies, peptides are relatively small in size (about 0.5 to 10 kDa) and are comparatively short in vivo circulation times (minutes to hours) with similar binding affinities. Besides, the production and modification of peptides, an effective strategy to improve affinity, selectivity, stability, and pharmacokinetic properties, is easier than that of antibodies. Notably, the biological half-life of peptides ideally matches that of radioactive particles currently used in radiopharmaceuticals.

Radionuclide-Peptide Conjugation

The conjugation between peptide and radionuclide requires a chelator that stably chelates the radioactive particles to eliminate the deposition of free radionuclide in healthy tissues in the patient body. The versatile and universal chelators, with similar chemical properties, enabled the development of RDC to provide more efficient, accurate, and personalized treatment, because of the availability of a wide range of radionuclides and targeting molecules in RDC. Myriad types of bioconjugation strategies are utilized in the radionuclide-peptide conjugation.

Fig.1 Bioconjugation strategies in RDC.
(Eric W. Price and Chris Orvig, Chem. Soc. Rev., 2014)